Caris Life Sciences Revenue Rises 27%
The Irving-based precision oncology company reported third quarter 2026 results and raised its full-year revenue outlook.
Updated on Nov. 5, 2026 in Healthcare
Caris Life Sciences reported third quarter 2026 revenue of $275.4 million, up 27% year over year, and raised its full-year 2026 revenue guidance to $1.04 billion to $1.05 billion. Results were released November 4, 2026.
Why it matters
Irving-based Caris Life Sciences is a precision oncology company whose molecular profiling volume and pricing drive its growth, and the revised outlook signals continued demand for its testing services. Operating expenses and cash outflows rose alongside revenue, reflecting ongoing investment in commercial expansion.
Operating expenses rose 42% to $163.0 million while net income fell to $15.3 million from $24.3 million a year earlier. Net cash used in operating activities was $22.2 million for the quarter, a 136% decline in operating cash flow year over year.
The players
Caris Life Sciences
Caris Life Sciences is a precision oncology company headquartered in Irving, Texas, offering molecular profiling tests such as Caris Assure and Caris Confirm.
The details
Revenue growth was driven primarily by higher clinical case volume, which reached approximately 61,500 cases in the quarter, up 21%, along with improvements in average selling price. Operating expense growth reflected headcount costs, increased research and development spending, and marketing expenditures.
Timeline
- March 3, 2026: Annual Report on Form 10-K filed with the SEC.
- September 30, 2026: Quarter end for the reported third quarter results.
- November 4, 2026: Third quarter results released and conference call held.
- Before year-end 2026: Caris Confirm targeted to launch.
Market Landscape
Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, extends the company's portfolio beyond Caris Assure, which is already available for therapeutic response monitoring. The company's expansion into residual disease testing positions it to compete in a segment of precision oncology focused on detecting cancer recurrence.
For Irving residents and patients whose physicians order molecular profiling, the company's expanding test menu and growing case volume reflect wider availability of tumor-based genomic testing. The reported cash outflow and higher spending indicate the company is still investing heavily in commercial growth.
The takeaway
Revenue growth and a higher guidance range point to strong demand for Caris Life Sciences' testing services. Investors and observers should watch whether rising operating expenses and cash outflows begin to ease as the company launches new products.
What happens next
Caris Confirm is targeted to launch before year-end 2026, and full-year 2026 revenue results will be reported against the $1.04 to $1.05 billion guidance range.
Further reading
For more on the industry behind this report, see Healthcare coverage from Irving.
More information
Review the quarterly results materials on the Caris Life Sciences investor relations website.
